Fighting for every beat: cardiac therapies in Duchenne muscular dystrophy

Antoine Muchir1

  • 1Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France. antoine.muchir@inserm.fr.

Skeletal Muscle
|September 8, 2025
PubMed

Insights

Duchenne muscular dystrophy (DMD) causes heart problems due to lack of dystrophin. This review explores new therapies to improve cardiac care for DMD patients.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Neuromuscular Disorders

Background:

  • Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by the absence of dystrophin.
  • Cardiac complications, including dilated cardiomyopathy and arrhythmias, are a major cause of mortality in DMD patients.
  • Degenerative changes in cardiac muscle mirror those in skeletal muscle, leading to heart failure.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for cardiac dysfunction in DMD.
  • To highlight advancements in managing heart complications associated with Duchenne muscular dystrophy.
  • To emphasize the importance of early detection and proactive cardiac care in DMD.

Main Methods:

  • This is a review article, synthesizing existing research and clinical findings.
  • The review focuses on therapeutic strategies targeting cardiac manifestations of DMD.
  • Information was gathered from scientific literature and clinical studies on DMD and cardiac care.

Main Results:

  • DMD leads to progressive cardiac muscle degeneration and heart failure.
  • Current research is exploring novel therapeutic avenues for DMD cardiac complications.
  • Effective management strategies are crucial for improving patient outcomes.

Conclusions:

  • Despite no definitive cure for DMD, significant progress is being made in cardiac care.
  • Emerging therapies hold promise for transforming treatment and improving quality of life for DMD patients.
  • Proactive cardiac management is essential for mitigating morbidity and mortality in Duchenne muscular dystrophy.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
343
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
263
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
416
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K